Table 1.
Key characteristics of people with cystic fibrosis (CF) in the two treatment groups.
| Short Infusion (30 min) | Extended Infusion (120 min) | |
|---|---|---|
| N = 6 | N = 6 | |
| Sex; n (%) | ||
| Female | 2 (33) | 3 (50) |
| Male | 4 (67) | 3 (50) |
| Genotypes; n (%) | ||
| Homozygous F508del | 2 (33) | 2 (33) |
| Heterozygous F508del | 2 (33) | 3 (50) |
| Other | 2 (33) | 1 (17) |
| Age; medium (SD) | 27.5 ± 8.04 | 26.67 ± 7.84 |
| BMI; medium (SD) | 20.07 ± 3.5 | 19.75 ± 2.71 |
| Best FEV1; medium (SD) | 36.67 ± 11.3 | 48 ± 15.67 |
| PA; n (%) | ||
| Yes | 5 (83) | 6 (100) |
| No | 1 (17) | 0 (0) |
| 3/4 MRGN PA; n (%) | 2 (33)/1 (17) | 0 (0) / 3 (50) |
| Combination therapy with tobramycin, n (%) | 5 (83) | 6 (100) |
| Laboratory results; medium (SD) | ||
| eGFR (mL/min) | 129.83 ± 6.27 | 129 ± 12.39 |
| ALT (U/L) | 26.33 ± 18.91 | 39.33 ± 27.63 |
| AST (U/L) | 36.17 ± 30.22 | 25 ± 8.74 |
| WBC (103/µL) | 11.55 ± 3.59 | 13.65 ± 3.15 |
| CRP (mg/L) | 32.81 ± 47.32 | 37.15 ± 40.21 |
Abbreviations; BMI: body mass index; FEV1: forced expiratory volume in 1 s; PA: Pseudomonas aeruginosa; 3/4 MRGN: 3/4 multidrug-resistant Gram-negative; eGFR: estimated glomerular filtration rate (creatinine-based; estimated by CKD-EPI-formula); ALT: alanine transaminase; AST: aspartate transaminase; CRP: C-reactive protein; WBC: white blood cells.